BPC 157: Miracle Healing Peptide or Hidden Danger? Sources: U.S. Food and Drug Administration (FDA) Compounding and the FDA (503A & 503B guidance) FDA warning letters on unapproved peptide products National Institutes of Health (NIH) PubMed FDA issued 30 warning letters to telehealth companies for false and misleading claims about compounded GLP 1 products. This marks the second round of enforcement action since the agency's September crackdown on misleading Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law